DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer.

Author(s): Kast RE

Affiliation(s): Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA. rekast@email.com

Publication date & source: 2009, Oncol Res., 17(8):383-6.

Publication type: Review

The 21 amino acid signaling peptide endothelin-1 is commonly elevated in epithelial ovarian cancer, and it mediates or facilitates much of this cancer's aggressive behavior. Ambrisentan (Letairis; Gilead Sciences Inc.) is an antagonist of endothelin-1 at its cognate receptor that has just been approved to treat pulmonary hypertension. Ambrisentan is a well-tolerated pill taken once daily. In theory, it should retard and inhibit lodgement and establishment of disseminated peritoneal micrometastases after debulking surgery.

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017